Analytical Project Leader
Responsible for analytical development from start of Phase 3 until first approvals (Brilinta project). Major achievements and responsibilities include:- Facilitated the smooth progression of the Brilinta project by working closely with other functions (Regulatory Affairs, Commercial Production Groups and other Development Teams) and by actively updating stakeholders of key project decisions;- Progressed regulatory submissions in face to face meetings with FDA, EMA (PAT team), Health Canada and Mexican regulatory authorities;- Guided the development of fast, cost-efficient and robust analytical methods for drug substance and drug product which were smoothly and successfully transferred to commercial production sites;- Influenced QbD development of Brilinta tablet manufacturing design space through close cross functional collaboration and provision of advice and analytical solutions to development issues;- Provided rapid and strategic analytical responses to regulatory questions from FDA, EMA, Health Canada, Australian TGA, Turkish Authorities, Malaysian and South Korea Authorities;- Managed the contracting out of NDA stability studies to a CRO and subsequent monitoring of stability data. Developed an excellent working relationship with the CRO that is now used as a model for other studies;- Initiated and implemented efficient cleaning verification procedures for pharnaceutical manufacturing equipment, resulting in significant time savings.